Catalog No.
PHE23501
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human CDKN1A (Met1-Pro164).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
CDKN1,MDA-6,Cyclin-dependent kinase inhibitor 1,CIP1,WAF1,CDKN1A,p21,PIC1,Melanoma differentiation-associated protein 6,MDA6,SDI1,CDK-interacting protein 1,CAP20
Concentration
0.56 mg/ml
Purification
Purified by antigen affinity column.
Accession
P38936
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation., PMID:40523897
Increased Fascin1 and Pak1 Expressions Enhance Age-Associated B-Cell Actin Cytoskeleton Remodeling and Motility., PMID:40500987
An Advanced IVB Lung Adenocarcinoma Patient With KRAS Mutations, Benefited From Camrelizumab Combined With Anti-Angiogenic Agents for Therapy: A Case Report., PMID:40488279
Retrospective stratified analysis of resistance mechanisms to anti-EGFR therapy in mCRC using tumor tissue samples., PMID:40467730
The presence of neutralizing antibodies against omicron subvariants among a vaccinated cohort at one year after the first dose of vaccination in Malaysia., PMID:40451847
Acetylation-induced degradation of ECHS1 enhances BCAA accumulation and proliferation in KRAS-mutant colorectal cancer., PMID:40437561
Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survival., PMID:40349418
HIV-Tat upregulates the expression of senescence biomarkers in CD4+ T-cells., PMID:40342418
Targeting the HER2-ELF3-KRAS axis: a novel therapeutic strategy for KRASG13D colorectal cancer., PMID:40340861
CD4-Positive T-Cell Responses to MOG Peptides in MOG Antibody-Associated Disease., PMID:40332104
A Novel Phosphorylated Tau Conformer Implicated in the Tauopathy Pathogenesis of Human Neurons., PMID:40305319
Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312., PMID:40304209
Increased protein expression of interleukin-10 and its signalling molecules in colon cancer progression: potential prognostic and therapeutic targets., PMID:40299210
A Child with Cutaneous-Skeletal Hypophosphatemia Syndrome Caused by a Mosaic HRAS Mutation: Outcome of Treatment with Anti-FGF23 Antibody., PMID:40295341
PAK5 promotes the trastuzumab resistance by increasing HER2 nuclear accumulation in HER2-positive breast cancer., PMID:40258843
Site-directed antibodies targeting driver mutations of the KRAS protein., PMID:40252917
Senescence-induced p21high macrophages contributed to CD8+ T cells-related immune hyporesponsiveness in kidney transplantation via Zfp36/IL-27 axis., PMID:40234384
JEV NS1' protein enhances cell-to-cell viral spread by inducing the formation of tunneling nanotubes., PMID:40187292
Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells., PMID:40172967
Glomerular mesangial cells derived complement factor H regulates complement activation, influences cell proliferation, and maintains actin cytoskeleton., PMID:40157080
BRAF V600E protein detection by immunohistochemistry in metastatic colorectal cancer tissue: association with tumor characteristics and KRAS mutation., PMID:40135701
An Anti-EGFR Antibody-Drug Radioconjugate Labeled with Actinium-225 Elicits Durable Antitumor Responses in KRAS- and BRAF-Mutant Colorectal Cancer., PMID:40126545
Ras-MAPK pathway in patients with lupus nephritis., PMID:40102014
Treatment of extended RAS/BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations., PMID:40097366
The emerging role of Sotorasib plus Panitumumab combination therapy in colorectal cancer treatment., PMID:40080361
Trastuzumab Decreases the Expression of G1/S Regulators and Syndecan-4 Proteoglycan in Human Rhabdomyosarcoma., PMID:40076757
Cost-Effectiveness Analysis of SOX Plus Bevacizumab Versus SOX Plus Cetuximab for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer in Japan., PMID:40038004
Genetic mutation in HSF4 is associated with retinal degeneration in mice., PMID:40023307
MAT2A Knockdown Enhances Recombinant Protein Expression in Transgenic CHO Cells Through Regulation of Cell Cycle., PMID:40011400
IL-6/GATA2/SERPINE1 pathway is implicated in regulating cellular senescence after acute kidney injury., PMID:40007559
Cost-effectiveness analysis of nimotuzumab combined with gemcitabine for K-Ras wild type locally advanced or metastatic pancreatic cancer in China., PMID:39984658
YY1 as a mediator to enhance the resistance of KRAS mutant colorectal cancer cells to cetuximab., PMID:39959936
NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model., PMID:39932765
Results of the Phase I/II Study and Preliminary B-cell Gene Signature of Combined Inhibition of Glutamine Metabolism and EGFR in Colorectal Cancer., PMID:39927885
Using methods to extend inferences to specific target populations to improve the precision of subgroup analyses., PMID:39924128
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors., PMID:39914665
Targeting the hERG1/β1 integrin complex in lipid rafts potentiates statins anti-cancer activity in pancreatic cancer., PMID:39900574
Human proximal tubular epithelial cell interleukin-1 receptor signalling triggers G2/M arrest and cellular senescence during hypoxic kidney injury., PMID:39890773
Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort., PMID:39856001
Elevated MCL1 expression drives esophageal squamous cell carcinoma stemness and induces resistance to radiotherapy., PMID:39831242
Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population., PMID:39805350
EGFR-targeting RNase A-cetuximab antibody-drug conjugate induces ROS-mediated apoptosis to overcome drug resistance in KRAS mutant cancer cells., PMID:39789190
Novel and potent MICA/B antibody is therapeutically effective in KRAS LKB1 mutant lung cancer models., PMID:39762078
[Annual therapeutic advances in advanced non-small cell lung cancer in 2024]., PMID:39757100
Efficacy of Combined Encorafenib and Binimetinib Treatment for Erdheim-Chester Disease Harboring Concurrent BRAFV600E and KRASG12R Mutations: A Case Report., PMID:39724464
Treatment with TNFα and lipolysis-stimulated lipoprotein receptor (LSR) antibody in the presence of HDAC inhibitors promotes apoptosis in human salivary duct adenocarcinoma., PMID:39676759
BoLA-DRB3 alleles influence proviral load and peripheral blood lymphocyte distribution in bovine leukaemia virus-infected cattle., PMID:39660663
Therapeutic Targeting and Structural Characterization of a Sotorasib-Modified KRAS G12C-MHC I Complex Demonstrate the Antitumor Efficacy of Hapten-Based Strategies., PMID:39656104
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors., PMID:39637943
Tissue factor signalling modifies the expression and regulation of G1/S checkpoint regulators: Implications during injury and prolonged inflammation., PMID:39611476
For research use only. Not for human or drug use.
